The Joint Committee on Vaccination and Immunization (JCVI) in the UK has recommended the use of Intercell’s Ixiaro to protect people at high risk of contracting Japanese Encephalitis.
Ixiaro is recommended for individuals aged 18 years and older that are at high risk of exposure during travel or in the course of their occupation.
The decision follows the expanded recommendations of the US Advisory Committee on Immunization Practices (ACIP) in 2009.
Gerd Zettlmeissl, Chief Executive Officer of Intercell, said: “We are pleased that our joint medical management efforts with our partner Novartis are materialising now also in Europe with the first country specific recommendations. Especially for novel travel vaccines recommendations are key to foster disease and product awareness and thus increasing vaccination rates and product uptake.”
Intercell AG is an biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Its novel Japanese Encephalitis vaccine, Ixiaro, is the company’s first product on the market.
Japanese Encephalitis is a mosquito-borne infection that causes 10,000 to 15,000 deaths each year and is the leading cause of viral neurological disease and disability in Asia.